ライフサイエンスコーパス: 5-bromodeoxyuridine

1 as preceded by 2 hour of pulse-labeling with 5-bromodeoxyuridine.

2 ular proliferation, as assessed by uptake of 5-bromodeoxyuridine.

3 d cells and incorporated into genomic DNA as 5-bromodeoxyuridine.

4 S phase cells were labeled in vivo with 5-bromodeoxyuridine.

5 DNA in these glands with a different marker, 5-bromodeoxyuridine (5BrdU), resulted in the appearance

6 ivated cross-linking of a self-complementary 5-bromodeoxyuridine (5BrU)-substituted oligonucleotide w

7 elevations in numbers of cells incorporating 5'-bromodeoxyuridine, a marker of unscheduled DNA synthe

8 ife by using two cell cycle-specific labels: 5-bromodeoxyuridine, a thymidine analog that labels cell

9 i) hypersensitivity to the nucleoside analog 5-bromodeoxyuridine and (ii) retention of more uracil re

10 tion (types I and III) and incorporated more 5-bromodeoxyuridine and TUNEL staining compared with uns

11 l detection of a marker for DNA replication (5-bromodeoxyuridine) and several cell type-specific mark

12 rve-tracing techniques, birth-date labeling (5-bromodeoxyuridine), and electrophysiology were used to

13 naive CD4+ T cells were labeled ex vivo with 5-bromodeoxyuridine as well as stained directly for Ki67

14 nd and those that occur after treatment with 5-bromodeoxyuridine, as these mutations are also drastic

15 identification, RPE cells were labeled with 5-bromodeoxyuridine, before intraocular transplantation.

16 Using 5'-bromodeoxyuridine birth dating we established that mo

17 Eosinophil levels and 5'-bromodeoxyuridine (BrdU) incorporation were examined

18 ymal cells as judged by the incorporation of 5'-bromodeoxyuridine (BrdU).

19 We have determined the in vivo effect of 5-bromodeoxyuridine (BrdU) administered to mice in the d

20 ilis chromosome with the nucleotide analogue 5-bromodeoxyuridine (BrdU) and for subcellular visualiza

21 HeLa cells were labeled with 5-bromodeoxyuridine (BrdU) at different times of S phase

22 quently we administered a cell cycle marker, 5-bromodeoxyuridine (BrdU) at early, middle or late peri

23 oximal tubular cells was detected by in vivo 5-bromodeoxyuridine (BrdU) incorporation on day 3.

24 the pro-mitotic growth factors with that of 5-bromodeoxyuridine (BrdU) incorporation to determine if

25 5-bromodeoxyuridine (BrdU) incorporation was used to exa

26 e kinetics using H2B-GFP label retention and 5-bromodeoxyuridine (BrdU) incorporation.

27 5-Bromodeoxyuridine (BrdU) labeling, proliferating cell

28 beling (TUNEL) to detect the dying cells and 5-bromodeoxyuridine (BrdU) to label newly generated cell

29 Forty-eight hour 5-bromodeoxyuridine (BrdU) uptake (used as an index of p

30 48 h later by intraperitoneal injections of 5-bromodeoxyuridine (BrdU), a marker for cell proliferat

31 reased proliferative activity assessed using 5-bromodeoxyuridine (BrdU), Ki-67, and c-Myc relative to

32 o retain labels such as the thymidine analog 5-bromodeoxyuridine (BrdU).

33 were identified by nuclear incorporation of 5-bromodeoxyuridine (BrdU; 7-day minipump infusion).

34 n cortex, using markers for DNA replication (5-bromodeoxyuridine; BrdU) and progressive neuronal diff

35 s and compared with that found using in vivo 5-bromodeoxyuridine (BrdUrd) labeling in formalin-fixed

36 ine perchlorate (DiI)], birth date labeling (5-bromodeoxyuridine), confocal microscopy, and electroph

37 Anti-5-bromodeoxyuridine immunolabeling revealed a significan

38 o myocardium induced DNA synthesis, shown by 5'-bromodeoxyuridine incorporation, and accumulation in

39 elevated proliferation rates as assessed by 5-bromodeoxyuridine incorporation and cell-cycle analysi

40 Analysis of 5-bromodeoxyuridine incorporation by these cells indicat

41 sustained in mitogen-restimulated myocytes, 5-bromodeoxyuridine incorporation experiments in serum-s

42 Analysis of 5-bromodeoxyuridine incorporation into DNA following inf

43 issociated cushion cells displayed increased 5-bromodeoxyuridine incorporation when infected with Q79

44 sing independent parameters of regeneration, 5-bromodeoxyuridine incorporation, proliferating cell nu

45 h the entry of cells into the cell cycle and 5-bromodeoxyuridine incorporation.

46 uated by hematoxylin and eosin histology and 5-bromodeoxyuridine incorporation.

47 ne, is detected on days 2 and 3 by increased 5-bromodeoxyuridine incorporation.

48 A mild increase in 5-bromodeoxyuridine labeling is observed in peripheral a

49 Comparison with 5-bromodeoxyuridine labeling of cells in S phase indicat

50 and ES cell-derived cardiomyocytes based on 5-bromodeoxyuridine labeling was similar, and immunocyto

51 However, pulse-chase 5-bromodeoxyuridine-labeling assay revealed that the sen

52 ealed a 7-fold increase in the percentage of 5-bromodeoxyuridine-positive cells and a 20-40-fold incr

53 , mtDNA (labeled with the thymidine analogue 5-bromodeoxyuridine) remained distinctly localized to on

54 5-Bromodeoxyuridine was used to label dividing cells.